Butterfly Network Inc., a digital health company specializing in handheld, whole-body ultrasound technology, announced that the European Commission has initiated the review and stakeholder consultation period for the company's request to revoke a specific exemption within the European Commission's Restriction of Hazardous Substances (RoHS) Directive. This exemption historically allowed the use of lead in single crystal piezoelectric materials for ultrasonic transducers. The Oeko-Institut has been appointed to conduct a technical assessment and third-party evaluation of this request. The stakeholder consultation will run from June 6, 2025, to August 1, 2025. A recommendation is expected by Q2 of 2026, with potential legal changes to follow 12 to 18 months after final adoption. Butterfly Network is optimistic about aligning ultrasound manufacturing with the EU's sustainability goals.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。